Cover Image
市場調查報告書

心肌炎 : 開發中產品分析

Myocarditis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302498
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
心肌炎 : 開發中產品分析 Myocarditis - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 33 Pages
簡介

心肌炎是指心臟肌肉發炎,一般是由於到達心臟的病毒、細菌、真菌感染造成。是發病率不高的疾病。主要症狀有胸痛和心跳數急增/異常、休息時或是身體活動時的呼吸困難、伴隨腿部·腳踝·腳腫脹的體液積留、倦怠感等。主要的治療方法有利用抗生素和抗發炎劑消除腫脹,利用利尿劑排放出過剩體液等。

本報告提供全球各國治療心肌炎所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心肌炎概要

治療藥的開發

  • 心肌炎開發中產品:概要
  • 心肌炎開發中產品:比較分析

各企業開發中的心肌炎治療藥

大學/研究機關研究中的心肌炎治療藥

開發中產品的概要

  • 初期階段的產品

心肌炎治療藥:開發中的產品一覽(各企業)

心肌炎治療藥:研究中的產品一覽(各大學/研究機關)

心肌炎治療藥的開發企業

  • CEL-SCI Corporation
  • GlaxoSmithKline Plc

心肌炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各分子類型

藥物簡介

  • CEL-1000
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 自體免疫性心肌炎IL-10 活性化細胞療法
  • 自體免疫性心肌炎Flt3L標的細胞療法
  • 南美錐蟲病疫苗
  • 適合心血管障礙的α肌凝蛋白抑制劑
  • OBR-5340
  • 適合心肌炎的克沙奇病毒B3 3C蛋白分解酵素的抑制劑

暫停中的計劃

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8424IDB

Summary

Global Markets Direct's, 'Myocarditis - Pipeline Review, H2 2016', provides an overview of the Myocarditis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocarditis
  • The report reviews pipeline therapeutics for Myocarditis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocarditis therapeutics and enlists all their major and minor projects
  • The report assesses Myocarditis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocarditis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocarditis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocarditis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocarditis Overview
  • Therapeutics Development
    • Pipeline Products for Myocarditis - Overview
    • Pipeline Products for Myocarditis - Comparative Analysis
  • Myocarditis - Therapeutics under Development by Companies
  • Myocarditis - Therapeutics under Investigation by Universities/Institutes
  • Myocarditis - Pipeline Products Glance
    • Early Stage Products
  • Myocarditis - Products under Development by Companies
  • Myocarditis - Products under Investigation by Universities/Institutes
  • Myocarditis - Companies Involved in Therapeutics Development
    • CEL-SCI Corporation
    • GlaxoSmithKline Plc
  • Myocarditis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBR-5340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myocarditis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocarditis, H2 2016
  • Number of Products under Development for Myocarditis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Myocarditis - Pipeline by CEL-SCI Corporation, H2 2016
  • Myocarditis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Myocarditis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Myocarditis, H2 2016
  • Number of Products under Development for Myocarditis - Comparative Analysis, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top